拉伏替丁
| 中文名称 | 拉伏替丁 |
|---|---|
| 中文同义词 | 拉伏替丁;化合物 T15722 |
| 英文名称 | Lavoltidine |
| 英文同义词 | 1-Methyl-5-[[3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-1H-1,2,4-triazole-3-methanol;1H-1,2,4-Triazole-3-methanol, 1-methyl-5-((3-(3-(1-piperidinylmethyl)phenoxy)propyl)amino)-;86160-82-9 (Hemisuccinate[1:1]);Lavoltidina;Lavoltidina [inn-spanish];Lavoltidine [inn:ban];Lavoltidinum;Lavoltidinum [inn-latin] |
| CAS号 | 76956-02-0 |
| 分子式 | C19H29N5O2 |
| 分子量 | 359.471 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 76956-02-0.mol |
| 结构式 |  |
拉伏替丁 性质
Lavoltidine (Loxtidine) 是一种具有口服活性的，不可逆且高效的组胺 H2 受体拮抗剂。Lavoltidine 强烈抑制胃酸分泌，并诱发高胃泌素血症。
|
H 2 Receptor
|
Lavoltidine (Loxtidine; 0.5 g/L; orally (drinking water); changed weekly; for 3 months) shows partial suppression of both gastric acid secretion and progression to neoplasia. Lavoltidine inhibits gastric atrophy, hyperplasia, and dysplasia in
H felis
-infected INS-GAS mice.
Lavoltidine treatment for 6 months inhibits gastric tumors in
H felis
-infected INS-GAS mice.
| Animal Model: | Male hypergastrinemic mice (INS-GAS mice) infected with Helicobacter felis |
| Dosage: | 0.5 g/L |
| Administration: | Orally (drinking water); changed weekly; for 3 months |
| Result: | Showed partial suppression of both gastric acid secretion and progression to neoplasia. |